Analysis of the Phase 3 PAOLA-1/ENGOT-ov25 Trial by Disease Stage in Patients with Homologous Recombination Deficiency–Positive Newly Diagnosed Advanced Ovarian Cancer Receiving Bevacizumab with Olaparib/Placebo Maintenance

2021 Year in Review - Ovarian Cancer - Ovarian Cancer

Results of the PAOLA-1/ENGOT-ov25 study demonstrated sustained progression-free survival benefit with the addition of maintenance olaparib to bevacizumab, compared with placebo and bevacizumab in homologous recombination deficiency-positive patients, irrespective of International Federation of Gynecology and Obstetrics stage and residual disease after up-front surgery.

Analyses of the phase 3 PAOLA-1/ENGOT-ov25 trial (NCT02477644), which evaluated the addition of maintenance olaparib or placebo to bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer (HGOC), were performed in homologous recombination deficiency (HRD)-positive patients by disease stage; these results were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

The study enrolled patients with newly diagnosed, International Federation of Gynecology and Obstetrics (FIGO) stage III-IV HGOC in response after platinum-based chemotherapy plus bevacizumab. Eligible patients received bevacizumab (15 mg/kg every 3 weeks for 15 months) and either olaparib (300 mg twice a day for 24 months) or placebo. This exploratory analysis evaluated progression-free survival (PFS; data cutoff: March 22, 2019) and second PFS (PFS2; data cutoff: March 22, 2020) in HRD-positive patients (tumor BRCA1/BRCA2 mutation [tBRCAm] or genomic instability score [Myriad myChoice HRD Plus] ≥42) by FIGO stage.

Of the 806 patients randomized in the study, 48% were HRD-positive. In the HRD-positive population, the majority (70%) had stage III disease, and 30% had stage IV disease; of whom 56% and 53% had a tBRCAm, respectively. Among patients with HRD-positive stage III disease, 63% had up-front surgery (of whom 30% had residual disease), and 33% had interval surgery (of whom 21% had residual disease). Among patients with HRD-positive stage IV disease, 45% had up-front surgery (of whom 65% had residual disease), and 48% had interval surgery (of whom 33% had residual disease).

Among patients with HRD-positive stage III disease, the olaparib/bevacizumab group (compared with the placebo/bevacizumab group) showed prolonged PFS (median follow-up: 24.8 months; median PFS: 39.3 vs 19.9 months) and PFS2 (median follow-up: 37.2 months; median PFS2: not reached vs 43.0 months). Among patients with HRD-positive stage IV disease, the olaparib/bevacizumab group showed prolonged PFS compared with the placebo/bevacizumab group (median follow-up: 24.0 months; median PFS: 25.1 vs 12.8 months, respectively), as well as PFS2 (median follow-up: 37.0 months; median PFS2: 37.8 vs 27.8 months, respectively). In lower-risk patients with stage III HRD-positive tumors, who benefited from complete resection following up-front surgery, the 2-year and 3-year PFS2 rates were >90% with olaparib/bevacizumab (94.7% and 91.9%, respectively) compared with placebo/bevacizumab (80.6% and 65.7%, respectively). Among higher-risk patients with stage III HRD-positive tumors and residual disease after up-front surgery, or those who received neoadjuvant chemotherapy, or those with HRD-positive stage IV disease, the 2-year PFS2 rate was 73.9%, and the 3-year PFS2 rate was 57.1% with olaparib/bevacizumab compared with placebo/bevacizumab (69.1% and 42.3%, respectively).

These results of the PAOLA-1 study demonstrate sustained PFS benefit with the addition of maintenance olaparib to bevacizumab compared with placebo plus bevacizumab in HRD-positive patients, irrespective of FIGO stage and residual disease after up-front surgery.

Source: Pautier P, Harter P, Pisano C, et al. Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial. J Clin Oncol. 2021;39(suppl_15). Abstract 5514.

Related Items
How to Sequence Treatment in Relapsed Ovarian Cancer
2021 Year in Review - Ovarian Cancer published on January 18, 2022 in Ovarian Cancer
Maintenance Gemogenovatucel-T Immunotherapy in Newly Diagnosed Advanced Ovarian Cancer
2021 Year in Review - Ovarian Cancer published on January 18, 2022 in Ovarian Cancer
Patient Self-Reporting of Tolerability in Phase 2 Trial Comparing Gemcitabine plus Adavosertib or Placebo in Women with Platinum-Resistant Epithelial Ovarian Cancer
2021 Year in Review - Ovarian Cancer published on January 18, 2022 in Ovarian Cancer
Mirvetuximab Soravtansine plus Bevacizumab in Patients with Recurrent Ovarian Cancer
2021 Year in Review - Ovarian Cancer published on January 18, 2022 in Ovarian Cancer
NeoPembrOV Study of Neoadjuvant Chemotherapy with or without Pembrolizumab Followed by Interval Debulking Surgery and Standard Systemic Therapy with or without Pembrolizumab for Advanced High-Grade Serous Carcinoma
2021 Year in Review - Ovarian Cancer published on January 18, 2022 in Ovarian Cancer
Optimal Treatment Duration of Bevacizumab plus Carboplatin/Paclitaxel in Advanced Ovarian Cancer
2021 Year in Review - Ovarian Cancer published on January 18, 2022 in Ovarian Cancer
Phase 1 Study of GAS6/AXL Inhibitor (AVB-500) in Recurrent, Platinum-Resistant Ovarian Carcinoma
2021 Year in Review - Ovarian Cancer published on January 18, 2022 in Ovarian Cancer
Anlotinib in Combination with TQB2450 in Patients with Recurrent Ovarian Cancer (ACTION)
2021 Year in Review - Ovarian Cancer published on January 18, 2022 in Ovarian Cancer
Niraparib Efficacy and Safety in Patients with BRCA-Mutated Ovarian Cancer from 3 Phase 3 Trials
2021 Year in Review - Ovarian Cancer published on January 18, 2022 in Ovarian Cancer
Real-World Treatment Patterns of Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer
2021 Year in Review - Ovarian Cancer published on January 18, 2022 in Ovarian Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: